Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MDVN > SEC Filings for MDVN > Form 8-K on 22-Oct-2012All Recent SEC Filings

Show all filings for MEDIVATION, INC.



Other Events

Item 8.01 Other Events.

On October 22, 2012, Medivation, Inc. issued the following statement regarding its oral androgen receptor inhibitor product XTANDIŽ (enzalutamide) capsules for the treatment of metastatic castration-resistant prostate cancer after docetaxel: XTANDI is distributed through select specialty pharmacies and specialty distributors to best meet the needs of patients. Given the proprietary nature of the data, our distribution partners generally will not be releasing the data to third party vendors like IMS Health.

  Add MDVN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MDVN - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.